Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2012

01-01-2012 | Original Article

Up-Regulated Expression of Advanced Glycation End-Products and Their Receptor in the Small Intestine and Colon of Diabetic Rats

Authors: Pengmin Chen, Jingbo Zhao, Hans Gregersen

Published in: Digestive Diseases and Sciences | Issue 1/2012

Login to get access

Abstract

Background and Aims

Gastrointestinal disorders and symptoms are common in diabetic patients. Advanced glycation end-products (AGEs) and their receptor (RAGE) have been proposed as an important pathological mechanism underlying diabetic complications, such as diabetic cardiopathy, retinopathy, nephropathy, etc. The aims were to study the distribution of AGE and RAGE in the normal and diabetic small intestine and colon in rats and the possible relationship between AGEs/RAGE and diabetes-induced intestinal structural remodeling.

Methods

Diabetic and age-matched normal rats survived for 56 days. The body weight and blood glucose were measured regularly until day 56. Jejunal, ileal, and colonic segments were excised. The wet weight per unit length and the layer thickness were measured. AGE and RAGE were detected by immunohistochemical staining.

Results

The wet weight per unit length in the three segments and the layer thickness in jejunum and ileum increased in the diabetic rats. The staining density of AGE in diabetic rats was higher in the villi of jejunum and ileum, and in the crypt and circumferential muscle layer of ileum compared to normal rats. The staining intensity of RAGE increased in ganglia, crypt, and brush border of diabetic jejunum and ileum as well as in ganglia of diabetic colon. Positive association was found between the accumulation of AGE and RAGE and the thickness of the different layers.

Conclusions

The expression of AGE and RAGE is up-regulated in the small intestine and colon of diabetic rats. The increased AGE and RAGE levels may contribute to diabetic GI dysfunction.
Literature
1.
go back to reference Nair M. Diabetes mellitus, part 1: physiology and complications. Br J Nurs. 2007;16:184–188.PubMed Nair M. Diabetes mellitus, part 1: physiology and complications. Br J Nurs. 2007;16:184–188.PubMed
2.
go back to reference Horowitz M, Samsom M. Gastrointestinal function in diabetes mellitus. Chichester: Wiley; 2004.CrossRef Horowitz M, Samsom M. Gastrointestinal function in diabetes mellitus. Chichester: Wiley; 2004.CrossRef
3.
go back to reference Zhao J, Frøkjaer JB, Drewes AM, Ejskjaer N. Upper gastrointestinal sensory-motor dysfunction in diabetes mellitus. World J Gastroenterol. 2006;12:2846–2857.PubMed Zhao J, Frøkjaer JB, Drewes AM, Ejskjaer N. Upper gastrointestinal sensory-motor dysfunction in diabetes mellitus. World J Gastroenterol. 2006;12:2846–2857.PubMed
4.
go back to reference Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44:129–146.PubMedCrossRef Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44:129–146.PubMedCrossRef
5.
go back to reference Bierhaus A, Humpert PM, Morcos M. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005;83:876–886.PubMedCrossRef Bierhaus A, Humpert PM, Morcos M. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005;83:876–886.PubMedCrossRef
6.
go back to reference Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev. 2002;1:1–15.PubMedCrossRef Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev. 2002;1:1–15.PubMedCrossRef
7.
go back to reference Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93:1143–1152.PubMedCrossRef Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93:1143–1152.PubMedCrossRef
8.
go back to reference Kato T, Yamashita T, Sekiguchi A, et al. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol. 2008;19:415–420.PubMedCrossRef Kato T, Yamashita T, Sekiguchi A, et al. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol. 2008;19:415–420.PubMedCrossRef
9.
go back to reference Chen BH, Jiang DY, Tang LS. Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes. Life Sci. 2006;79:1040–1048.PubMedCrossRef Chen BH, Jiang DY, Tang LS. Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes. Life Sci. 2006;79:1040–1048.PubMedCrossRef
10.
go back to reference Sugiyama T, Okuno T, Fukuhara M, et al. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp Eye Res. 2007;85:406–412.PubMedCrossRef Sugiyama T, Okuno T, Fukuhara M, et al. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp Eye Res. 2007;85:406–412.PubMedCrossRef
11.
go back to reference Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des. 2008;14:946–952.PubMedCrossRef Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des. 2008;14:946–952.PubMedCrossRef
12.
go back to reference Suzuki D, Toyoda M, Yamamoto N, et al. Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. Intern Med. 2006;45:435–441.PubMedCrossRef Suzuki D, Toyoda M, Yamamoto N, et al. Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. Intern Med. 2006;45:435–441.PubMedCrossRef
13.
go back to reference Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Seminars in Nephrology. 2007;27:130–143.PubMedCrossRef Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Seminars in Nephrology. 2007;27:130–143.PubMedCrossRef
14.
go back to reference Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis. 2008;196:9–21.PubMedCrossRef Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis. 2008;196:9–21.PubMedCrossRef
15.
go back to reference Peppa M, Raptis SA. Advanced glycation end products and cardiovascular disease. Curr Diabetes Rev. 2008;4:92–100.PubMedCrossRef Peppa M, Raptis SA. Advanced glycation end products and cardiovascular disease. Curr Diabetes Rev. 2008;4:92–100.PubMedCrossRef
16.
go back to reference Ling X, Nagai R, Sakashita N, et al. Immunohistochemical distribution and quantitative biochemical detection of advanced glycation end products in fetal to adult rats and in rats with streptozotocin- induced diabetes. Lab Invest. 2001;81:845–861.PubMed Ling X, Nagai R, Sakashita N, et al. Immunohistochemical distribution and quantitative biochemical detection of advanced glycation end products in fetal to adult rats and in rats with streptozotocin- induced diabetes. Lab Invest. 2001;81:845–861.PubMed
17.
go back to reference Bhor VM, Sivakami S. Regional variations in intestinal brush border membrane fluidity and function during diabetes and the role of oxidative stress and non-enzymatic glycation. Mol Cell Biochem. 2003;252:125–132.PubMedCrossRef Bhor VM, Sivakami S. Regional variations in intestinal brush border membrane fluidity and function during diabetes and the role of oxidative stress and non-enzymatic glycation. Mol Cell Biochem. 2003;252:125–132.PubMedCrossRef
18.
go back to reference Jeyabal PV, Kumar R, Gangula PR, et al. Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats. Neurogastroenterol Motil. 2008;20:253–261.PubMedCrossRef Jeyabal PV, Kumar R, Gangula PR, et al. Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats. Neurogastroenterol Motil. 2008;20:253–261.PubMedCrossRef
19.
go back to reference Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci. 2005;1043:598–604.PubMedCrossRef Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci. 2005;1043:598–604.PubMedCrossRef
20.
go back to reference Nazratun N, Mahmood AA, Kuppusamy UR, et al. Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients. Vasc Med. 2006;11:245–250.PubMedCrossRef Nazratun N, Mahmood AA, Kuppusamy UR, et al. Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients. Vasc Med. 2006;11:245–250.PubMedCrossRef
21.
go back to reference Esposito C, Gerlach H, Brett J, et al. Endothelial receptor-mediated binding of glucose modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med. 1989;170:1387–1407.PubMedCrossRef Esposito C, Gerlach H, Brett J, et al. Endothelial receptor-mediated binding of glucose modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med. 1989;170:1387–1407.PubMedCrossRef
22.
go back to reference Schmidt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation endproducts: implications for induction of oxidative stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994;14:1521–1528.PubMedCrossRef Schmidt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation endproducts: implications for induction of oxidative stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994;14:1521–1528.PubMedCrossRef
23.
go back to reference Vlassara H. Receptor mediated interactions of advanced glycosylation endproducts with cellular components within diabetic tissues. Diabetes. 1991;41:52–56. Vlassara H. Receptor mediated interactions of advanced glycosylation endproducts with cellular components within diabetic tissues. Diabetes. 1991;41:52–56.
24.
go back to reference Vlassara H, Bucala R, Striker LJ. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994;70:138–151.PubMed Vlassara H, Bucala R, Striker LJ. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994;70:138–151.PubMed
25.
go back to reference Zoubi SA, Mayhew TM, Sparrow RA. The small intestine in experimental diabetes: cellular adaptation in crypts and villi at different longitudinal sites. Virchows Arch. 1995;426:501–507.PubMedCrossRef Zoubi SA, Mayhew TM, Sparrow RA. The small intestine in experimental diabetes: cellular adaptation in crypts and villi at different longitudinal sites. Virchows Arch. 1995;426:501–507.PubMedCrossRef
26.
go back to reference Mayhew TM, Carson FL. Mechanisms of adaptation in rat small intestine: regional differences in quantitative morphology during normal growth and experimental hypertrophy. J Anat. 1995;164:189–200. Mayhew TM, Carson FL. Mechanisms of adaptation in rat small intestine: regional differences in quantitative morphology during normal growth and experimental hypertrophy. J Anat. 1995;164:189–200.
27.
go back to reference Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol. 2004;165:2033–2043.PubMedCrossRef Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol. 2004;165:2033–2043.PubMedCrossRef
28.
go back to reference Murata T, Nagai R, Ishibashi T, et al. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 1997;40:764–769.PubMedCrossRef Murata T, Nagai R, Ishibashi T, et al. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 1997;40:764–769.PubMedCrossRef
29.
go back to reference Rumble JR, Cooper ME, Soulis T, et al. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest. 1997;99:1016–1027.PubMedCrossRef Rumble JR, Cooper ME, Soulis T, et al. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest. 1997;99:1016–1027.PubMedCrossRef
30.
go back to reference Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest. 2001;108:1853–1863.PubMed Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest. 2001;108:1853–1863.PubMed
31.
go back to reference Seki N, Hashimoto N, Sano H, et al. Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells. Metabolism. 2003;52:1558–1563.PubMedCrossRef Seki N, Hashimoto N, Sano H, et al. Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells. Metabolism. 2003;52:1558–1563.PubMedCrossRef
32.
go back to reference Handa JT, Reiser KM, Matsunaga H, Hjelmeland LM. The advanced glycation endproduct pentosidine induces the expression of PDGF-B in human retinal pigment epithelial cells. Exp Eye Res. 1998;66:411–419.PubMedCrossRef Handa JT, Reiser KM, Matsunaga H, Hjelmeland LM. The advanced glycation endproduct pentosidine induces the expression of PDGF-B in human retinal pigment epithelial cells. Exp Eye Res. 1998;66:411–419.PubMedCrossRef
33.
go back to reference Chandrasekharan B, Srinivasan S. Diabetes and the enteric nervous system. Neurogastroenterol Motil. 2007;19:951–960.PubMed Chandrasekharan B, Srinivasan S. Diabetes and the enteric nervous system. Neurogastroenterol Motil. 2007;19:951–960.PubMed
34.
go back to reference Guyton AC, Hall JE. Textbook of medical physiology. 10th ed. USA: W.B. Saunders Company; 2000:754–763. Guyton AC, Hall JE. Textbook of medical physiology. 10th ed. USA: W.B. Saunders Company; 2000:754–763.
35.
go back to reference Brasitus TA, Dudeja PK. Correction of abnormal lipid fluidity and composition of rat ileal microvillus membranes in chronic streptozotocin induced diabetes by insulin therapy. J Biol Chem. 1985;260:12405–12409.PubMed Brasitus TA, Dudeja PK. Correction of abnormal lipid fluidity and composition of rat ileal microvillus membranes in chronic streptozotocin induced diabetes by insulin therapy. J Biol Chem. 1985;260:12405–12409.PubMed
36.
go back to reference Olsen WA, Korsmo H. The intestinal brush border membrane in diabetes. Studies of sucrase-isomaltase metabolism in rats with streptozotocin diabetes. J Clin Invest. 1977;60:181–188.PubMedCrossRef Olsen WA, Korsmo H. The intestinal brush border membrane in diabetes. Studies of sucrase-isomaltase metabolism in rats with streptozotocin diabetes. J Clin Invest. 1977;60:181–188.PubMedCrossRef
37.
go back to reference Keelan M, Walker K, Thomson AB. Intestinal brush border membrane marker enzymes, lipid composition and villus morphology: effect of fasting and diabetes mellitus in rats. Comp Biochem Physiol A Comp Physiol. 1985;82:83–89.PubMedCrossRef Keelan M, Walker K, Thomson AB. Intestinal brush border membrane marker enzymes, lipid composition and villus morphology: effect of fasting and diabetes mellitus in rats. Comp Biochem Physiol A Comp Physiol. 1985;82:83–89.PubMedCrossRef
38.
go back to reference Phillips LK, Rayner CK, Jones KL, Horowitz M. An update on autonomic neuropathy affecting the gastrointestinal tract. Curr Diab Rep. 2006;6:417–423.PubMedCrossRef Phillips LK, Rayner CK, Jones KL, Horowitz M. An update on autonomic neuropathy affecting the gastrointestinal tract. Curr Diab Rep. 2006;6:417–423.PubMedCrossRef
39.
go back to reference King RH. The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol Pathol. 2001;54:400–408.PubMed King RH. The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol Pathol. 2001;54:400–408.PubMed
40.
go back to reference Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy—are these receptors valid therapeutic targets. Curr Drug Targets. 2009;10:42–50.PubMedCrossRef Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy—are these receptors valid therapeutic targets. Curr Drug Targets. 2009;10:42–50.PubMedCrossRef
41.
go back to reference Toth C, Martinez J, Zochodne DW. RAGE, diabetes, and the nervous system. Curr Mol Med. 2007;7:766–776.PubMedCrossRef Toth C, Martinez J, Zochodne DW. RAGE, diabetes, and the nervous system. Curr Mol Med. 2007;7:766–776.PubMedCrossRef
42.
go back to reference Russo A, Fraser R, Adachi K, et al. Evidence that nitric oxide mechanisms regulate small intestinal motility in humans. Gut. 1999;44:72–76.PubMedCrossRef Russo A, Fraser R, Adachi K, et al. Evidence that nitric oxide mechanisms regulate small intestinal motility in humans. Gut. 1999;44:72–76.PubMedCrossRef
43.
go back to reference Korenaga K, Micci MA, Taglialatela G, Pasricha PJ. Suppression of nNOS expression in rat enteric neurones by the receptor for advanced glycation end-products. Neurogastroenterol Motil. 2006;18:392–400.PubMedCrossRef Korenaga K, Micci MA, Taglialatela G, Pasricha PJ. Suppression of nNOS expression in rat enteric neurones by the receptor for advanced glycation end-products. Neurogastroenterol Motil. 2006;18:392–400.PubMedCrossRef
44.
go back to reference Toth C, Rong LL, Yang C, et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes. 2008;57:1002–1017.PubMedCrossRef Toth C, Rong LL, Yang C, et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes. 2008;57:1002–1017.PubMedCrossRef
Metadata
Title
Up-Regulated Expression of Advanced Glycation End-Products and Their Receptor in the Small Intestine and Colon of Diabetic Rats
Authors
Pengmin Chen
Jingbo Zhao
Hans Gregersen
Publication date
01-01-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1951-0

Other articles of this Issue 1/2012

Digestive Diseases and Sciences 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine